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ABSTRACT 
 
A prominent feature of many human cancers is oncogene-driven activation of the DNA damage 
response (DDR) during early tumorigenesis. It has been shown previously that non-invasive 
imaging of γH2AX, a DNA damage signaling protein, is possible using 111In-labeled anti-
γH2AX antibody conjugated to the cell-penetrating peptide, TAT. The purpose of this study was 
to investigate whether 111In-anti-γH2AX-TAT detects the DDR during mammary oncogenesis in 
BALB-neuT mice.  
Methods: Mammary fat pads from BALB-neuT and wild-type mice (aged 40-106 days) were 
immunostained for γH2AX. 111In-anti-γH2AX-TAT or a control probe was administered 
intravenously to BALB-neuT mice. Single-photon emission computed tomography (SPECT) 
was performed weekly and compared to tumor detection using palpation and DCE-MRI imaging.  
Results: γH2AX expression was elevated in hyperplastic lesions in the mammary fat pads of 
BALB-neuT mice aged 76-106 days compared to normal fat pads from younger mice and 
carcinomas from older mice (13.5±1.2 γH2AX foci/cell versus 5.2±1.5 [P<0.05] and 3.4±1.1 
[P<0.001], respectively). Serial SPECT imaging revealed a 2.5-fold increase in 111In-anti-
γH2AX-TAT accumulation in the mammary fat pads of mice aged 76-106 days, compared to 
control probe (P=0.01). The median time to detection of neoplastic lesions by 111In-anti-γH2AX-
TAT (defined as >5% injected dose per gram of tissue) was 96 days compared to 120 and 131 
days for DCE-MRI and palpation, respectively (P<0.001).  
Conclusion: DDR-imaging using 111In-anti-γH2AX-TAT identified mammary tumors 
significantly earlier than MRI. Imaging the DDR holds promise for the detection of preneoplasia 
and as a technique for screening cancer-prone individuals. 
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INTRODUCTION 
 
The DNA damage response (DDR) is a highly regulated cellular process that follows 
exposure to ionizing radiation (IR) and other genotoxic insults (1). The DDR is activated during 
the earliest stages of cancer development, when it is triggered by the onset of oncogenic stress. 
Signaling via the ATM-Chk2-p53 DDR pathway minimizes genomic instability and inhibits cell 
cycle progression and tumor formation (2). This protective mechanism is eventually overridden, 
possibly precipitated by mutations of the p53 gene (3). Early reports of DDR activation during 
bladder, colon, breast, skin and lung cancer development showed that it was accompanied by the 
activation of signaling proteins downstream of pATM, including pChk2 and γH2AX (4, 5). DDR 
activation has since been observed to occur during the development of many other types of cancer 
including pancreatic (6), ovarian (7) and hepatocellular carcinomas (8). Given the near ubiquitous 
nature of DDR activation during oncogenesis, it has been suggested that markers of DNA 
replication stress and constitutive DDR activation might distinguish neoplastic growth from 
normal tissues. This has been substantiated by immunohistochemical analyses of human tissues. 
In one study markers of DDR activation were observed only in sub-populations of lymphocytic 
cells in bone marrow, spermatocytes in adult testes and basal esophageal cells (4). This raises the 
possibility that detection of DDR activation in vivo could allow early detection of precancerous 
and cancerous lesions (9). 
It has been shown previously that an anti-γH2AX antibody-based imaging probe can detect 
γH2AX non-invasively (10). Anti-γH2AX antibodies were modified by the addition of the HIV-1 
transactivator of transcription protein-derived cell-penetrating peptide, TAT, which harbors a non-
classical nuclear localization sequence, promoting nuclear translocation of the conjugate. Anti-
γH2AX-TAT was radiolabeled with indium-111 (111In), to allow SPECT imaging. Following 
induction of γH2AX by X-irradiation or bleomycin, 111In-anti-γH2AX-TAT accumulated in 
human breast cancer xenografts in athymic mice, and the extent of 111In uptake was linearly 
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dependent on the level of γH2AX expression (10). 
In this report the ability of the 111In-anti-γH2AX-TAT probe to detect DDR during 
tumorigenesis was investigated using a transgenic mouse model of breast cancer in which the 
mouse mammary tumor virus (MMTV) promoter drives neuT expression. NeuT, a variant of the 
rat neu HER2-homolog, contains a point mutation in the transmembrane region and is highly 
tumorigenic compared to wild-type (WT) neu or human HER2 (11). When BALB-neuT mice 
reach 21-28 days of age, the neuT protein is over-expressed in mammary glands and areas of 
atypical hyperplasia start to form (12). These progress to in situ carcinomas at about day 60 and 
to invasive cancers by day 120-150. Neoplastic change occurs, albeit asynchronously, in all 
mammary glands so that by about 120 days one or more tumors are palpable and by about day 
230 (33 weeks) all 10 mammary glands contain palpable tumors (13). In this study we explored 
the ability of 111In-anti-γH2AX-TAT SPECT imaging to detect tumors during oncogenesis in 
BALB-neuT mice. 
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MATERIALS AND METHODS 
 
Animal Model 
All animal procedures were carried out in accordance with the UK Animals (Scientific 
Procedures) Act 1986 and with local ethical committee approval. Female WT BALB/c mice 
(Charles River, Wilmington, MA, USA) were crossed with male BALB-neuT mice (gift from 
Guido Forni). The BALB-neuT strain originated from a transgenic CD1 random-bred breeder 
male mouse carrying the mutated rat neuT oncogene driven by the MMTV promoter (1). The 
mutated gene encodes a single point mutation that replaces the valine residue at position 664 in 
the transmembrane (TM) domain of p185/neu with glutamic acid. This mutation promotes p185 
homo- and heterodimerization and transforms the neu protooncogene into a dominant 
transforming oncogene. Offspring of the BALB-neuT male and WT female cross were genotyped 
using the following primers: 5'-CGCACGTCCTCCAGGTAG-3' and 5'-
GATTCCAACGACCACCACTA-3'. NeuT-positive female mice were used for experiments. 
 
Immunohistochemistry 
At selected time points, mammary tissue or mammary tumors were harvested from 
female BALB/c or BALB-neuT mice. Flash frozen tissues were embedded in OCT and 10 μm 
sections were prepared. Tissue sections were stained with haematoxylin/eosin and images were 
acquired using a wide-field microscope. Alternatively, sections were washed to remove OCT, 
fixed (4% PFA, 10 min, room temperature), permeabilized (1% triton X-100 in PBS, 10 min, 
room temperature), blocked (1% BSA in PBS, 1 h, 37 °C), and incubated with anti-γH2AX 
antibodies raised in mouse (Calbiochem, Millipore, Watford, UK; 1:800 in blocking buffer, 1 h, 
37 °C), or with anti-pATM antibodies raised in rabbit (R&D Systems, Minneapolis, MN, USA), 
followed by AlexaFluor488(AF488)-labeled goat anti-mouse or AlexaFluor555(AF555)-labeled 
goat anti-rabbit antibody (Invitrogen, Paisley,UK; 1:250 in blocking buffer, 1 h, 37 °C). Sections 
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were mounted with Vectashield containing DAPI to stain DNA (Vector Laboratories, 
Peterborough, UK), and images were acquired using confocal microscopy (Zeiss 710; Carl Zeiss 
Ltd., Welwyn Garden City, UK). Enumeration of γH2AX foci was performed manually in >1500 
cells per samples, on >10 randomly selected view fields. 
 
In Vivo Imaging and Biodistribution 
111In-anti-γH2AX-TAT and the non-specific control probe, 111In-rabbitIgG-TAT (111In-
rIgG-TAT), and the fluorophore-labeled probe, Cy3-anti-γH2AX-TAT, were synthesized as 
reported (10). SPECT and CT images of BALB-neuT mice aged between 43 and 145 days were 
acquired under isoflurane anesthesia using a small animal nanoSPECT/CT scanner (Bioscan, 
Washington DC), 24 h after i.v. administration of 111In-anti-γH2AX-TAT (5 µg; 16 animals) or 
111In-rIgG-TAT (5 µg; 16 animals). Imaging was repeated weekly for part of the period between 
the ages of 43 and 145 days per animal (5 MBq 111In per scan). Animals were euthanized when 
tumor size reached the permitted upper limit (12 mm gross median diameter). Volume of interest 
(VOI) analysis of mammary fat pads and selected normal tissues was performed using the Inveon 
Research Workplace package (Siemens, Camberley, UK). 111In uptake in mammary fat pads and 
the age of animals were recorded. Tumors were scored as positive when the percentage of the 
injected dose per gram of tissue (%ID/g) exceeded 5%ID/g. 111In-anti-γH2AX-TAT (5 µg) was 
administered i.v. to BALBc WT mice. Following acquisition of SPECT images at 24 h p.i., mice 
were euthanized and organs were removed, weighed, and counted for radioactivity. To 
demonstrate γH2AX targeting in vivo BALB-neuT or BALB/c WT mice aged 80 to 100 days (3 
mice per group) received Cy3-anti-γH2AX-TAT (5 µg) or PBS intravenously (i.v.). At 24 h 
post-injection (p.i.), fluorescence imaging was performed, using an IVIS200 system (Perkin 
Elmer, Waltham, MA, USA), as described previously (10). Mammary fat pads were removed, 
flash frozen, sectioned and processed for γH2AX immunostaining.  
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MRI Imaging 
T1-weighed and dynamic contrast enhanced MRI (DCE-MRI) imaging of BALB-neuT 
mice of different ages was performed before and 20 min after i.v. administration of Omniscan (15 
µmol, 0.5 M gadodiamide; GE Healthcare, Amersham, UK), using a dedicated small-animal 
MRI. Data were collected using a T1-weighted, gradient and RF spoiled, respiration triggered, 3-
D gradient-echo sequence on a Varian/Agilent 4.7T MRI camera (Agilent, Yarnton, UK). 
Imaging parameters were: flip angle = 10º; TR=2.06 ms; TE=0.93 ms; FOV=54 x 27 x 27 mm3; 
isotropic 420 µm resolution; 11 s temporal resolution. After acquisition of 10 frames, 15 µmol 
Omniscan™ was injected intravenously over 5 s via a catheter placed in a tail vein. Images were 
acquired for a further 20 minutes. Semi-quantitative Gd-uptake parameters (area-under-the-curve 
(AUC), first uptake moment) on a voxel-per-voxel basis were extracted for the whole tumour 
using Matlab, and parametric images generated. Images were inspected, and where tumors larger 
than 3x3 voxels was found, mice were scored as positive. 
 
Statistical Methods 
All data and graphs are expressed as mean ± one standard deviation, unless defined 
otherwise. Differences in the number of γH2AX foci/cell were assessed using an ANOVA test. 
Differences in the uptake of 111In-anti-γH2AX-TAT and 111In-rIgG-TAT were assessed by fitting 
a multilevel linear model with age, compound and set (data were obtained in two independent sets 
of n = 20 and n = 12) as explanatory variables. An interaction between age and compound was 
fitted to allow different effects of age for each compound. The uptake of 111In-anti-γH2AX-TAT 
and 111In-rIgG-TAT in mice of each age group was compared by fitting a multilevel linear model. 
Age groups were chosen based on known timing of development of mammary fat pad lesions in 
the BALB-neuT model. As a sensitivity analysis, ‘nil’ measurements, where no VOI could be 
drawn, since no signal/structure was discernable, were excluded and the models were fitted 
again, but this variation did not alter the conclusion. Times to tumor detection by SPECT, MRI 
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and palpation were compared using log-rank tests. All statistical analyses were performed using 
the statistical software package R (14). 
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RESULTS 
 
DDR Activation During Carcinogenesis in BALB-neuT Mice 
Histological examination of mammary fat pads from BALB-neuT mice confirmed the 
progressive development of atypical hyperplasia and in situ lesions, leading to invasive 
carcinoma by the age of 100-130 days (Fig. 1A). Normal duct structure was observed in 
mammary fat pads of mice aged up to 40 days. By 75 days changes of atypical hyperplasia were 
noted consisting of dilated, irregular ducts with pleomorphic cells containing enlarged nuclei. At 
90-95 days there was extensive atypical hyperplasia with in situ carcinoma, typified by thickened 
ductal walls and small intra-ductal masses. Invasive carcinomas were apparent at 100-130 days 
(solid masses). In contrast, mammary fat pads from WT BALB/c mice aged 130 days showed 
normal histology (Supplementary Fig. S1A and S1B). DDR activation, as indicated by the 
phosphorylation of H2AX to form γH2AX, was observed in hyperplastic lesions and DCIS-like 
mammary fat pad lesions in BALB-neuT mice at 75 to 95 days (Fig. 1A). Also, although 
staining for total ATM in mammary fat pads/tumors was positive, with low-level expression at 
all time points tested, the activated form (pATM) of the enzyme was only clearly present at 75-
95 days, further evidence of up-regulation of the DDR during this phase. The number of γH2AX 
foci was greater in hyperplastic lesions in mammary fat pads from mice aged 76-106 days than 
in mammary fat pads from mice aged <75 days (13.5±1.2 versus 5.2±1.5 foci/cell; P<0.05), and 
in carcinomas from mice aged >106 days (13.5±1.2 versus 3.4±1.1 foci/cell; P<0.001) (Fig. 1B). 
  
Targeting γH2AX In Vivo  
To confirm that systemically delivered anti-γH2AX-TAT probe co-localizes with 
γH2AX in vivo, fluorescence imaging of BALB-neuT or WT BALB/c mice (aged 80-100 days) 
was performed 24 h after i.v. administration of Cy3-anti-γH2AX-TAT. The fluorescent signal 
localized in mammary fat pads in BALB-neuT mice (Fig. 2A). No fluorescent signal was 
observed in fat pads of BALB/c mice or in BALB-neuT mice that received PBS i.v. A feature of 
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the BALB-neuT model is the development of lymph node metastases. Also, while the neuT 
oncogene is mainly expressed in mammary glands, it is expressed to a lesser extent in salivary 
glands. Therefore some of the areas of uptake may represent lymph node or salivary gland 
deposits. Mammary tissue was harvested and immunostained for γH2AX. Co-localization of 
Cy3-anti-γH2AX-TAT (red) and γH2AX foci (green) was observed (Fig. 2B). 
 
111In-anti-γH2AX-TAT SPECT Imaging  
To study γH2AX expression, as a marker of DDR activation, throughout the progression 
of mammary fat pad lesions, BALB-neuT mice were imaged weekly using SPECT, 24 h after 
administration of 111In-anti-γH2AX-TAT i.v. The data consist of 148 observations on 32 animals, 
obtained in 2 sets of n=20 and n=12 (Fig. 3A-C). Restriction on the number of weekly scans each 
animal underwent meant that no single animal was imaged throughout the entire period of interest 
(from 40-130 days). However, a complete time course that includes measurements from all mice 
is presented (Fig. 3C).  Plots for individual animals for which at least 4 observations were made 
are shown in Supplementary Fig. S2. The uptake of 111In-anti-γH2AX-TAT was higher than that 
of 111In-rIgG-TAT (P=0.0038; adjusted for age and set). Intratumoral accumulation of both 111In-
anti-γH2AX-TAT and 111In-rIgG-TAT was high in older mice (>106 days), compared to younger 
mice. This suggests that non-specific enhanced permeability and retention (EPR)-mediated uptake 
of IgG-TAT constructs occurs in mature tumors. This may be attributable to leakiness of vessels 
in large, fully established tumors. In mice aged less than 76 days, tumor uptake of 111In-anti-
γH2AX-TAT and 111In-rIgG-TAT did not differ significantly (2.52±2.02 versus 1.42±1.72 %ID/g, 
respectively). This was consistent with the multilevel model in which the coefficient for 111In-anti-
γH2AX-TAT was estimated to be 1.19±0.92, P=0.24. That is, for the 111In-anti-γH2AX-TAT 
group the uptake for ages <76 days is expected to be 1.19 higher than in the 111In-rIgG-TAT 
group. However, 111In-anti-γH2AX-TAT accumulated to a greater extent than 111In-rIgG-TAT in 
the mammary fad pads of mice aged 76-106 days (3.67±3.01 versus 1.48±1.86 %ID/g, 
respectively; intercept 1.60±0.59 and beta for 111In-anti-γH2AX-TAT 2.22±0.80; P=0.01 for 
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beta), which corresponds to the development of in situ and early invasive carcinomas.  For this 
group 111In-anti-γH2AX-TAT uptake often exceeded 5%ID/g, whereas in only one case did the 
uptake of the control probe marginally exceed 5%ID/g. Additionally, analysis of data on 
individual lesions showed that all lesions that became palpable during the study had been 
identified by SPECT imaging before becoming detectable by palpation. In 14 out of 16 mice, the 
first lesion to be detected by 111In-anti-γH2AX-TAT SPECT imaging was subsequently also the 
first lesion to become palpable. 
111In-anti-γH2AX-TAT was administered to young or old BALB/c WT mice and 
following acquisition of SPECT images performed at 24 h followed by retrieval of tissues for 
radioactivity counting (Supplementary Fig. S3). Uptake of 111In-anti-γH2AX-TAT was slightly 
higher in the mammary fat pads of young versus old mice: however, this did not reach statistical 
significance (mean +/- SD: 2.28±0.35 versus 1.21±0.49; P=0.10).  The level of uptake in the 
mammary fat pads in BALB/c WT mice was therefore well below the 5%ID/g cut-off that was 
used to denote positive 111In-anti-γH2AX-TAT uptake in BALB-neuT mice.   
 
Lack of Effect of 111In-RICs on γH2AX Expression and Tumor Growth  
To evaluate the possibility that administration of 111In-anti-γH2AX-TAT or 111In-rIgG-
TAT could itself affect tumor development, the tumor-free survival of mice that had undergone 
repeated imaging was compared to that of control animals. No significant differences were 
detected (log rank test; P=0.41) (Fig. 4). Similarly, in a group of animals aged 89-96 days there 
was no statistical difference in the number of γH2AX foci/tumor cell in mice that received 111In-
anti-γH2AX-TAT compared to those that did not. The mean γH2AX foci/cell 24 h after a single 
i.v. injection of 111In-anti-γH2AX-TAT was 14.7±3.1 (n=12) versus 13.5±2.9 (n=6) for controls 
(P=0.65). 
 
Early Detection of Precancerous Lesions  
Small tumors were not identified in CT images, acquired to provide an anatomical 
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reference for SPECT images (results not shown). However, tumors with a diameter as small as 
1.26 mm were visualized using T1-weighed MRI images and were particularly clearly identifiable 
in AUC-parameter maps generated after DCE-MRI (Fig. 5A). The median age at which tumors 
were detectable by DCE-MRI and palpation was 120 and 131 days, respectively (P=0.10). SPECT 
imaging using 111In-anti-γH2AX-TAT was superior to DCE-MRI (P=0.058), with median age at 
detection of first tumor of 96 days (Fig. 5B). 
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DISCUSSION 
Oncogenic stimulation leading to DNA replication stress occurs early in the development 
of cancer. The resulting accumulation of DNA damage triggers constitutive activation of the DDR, 
typified by expression of phosphorylated forms of key DNA repair proteins including pATM 
(S1981), γH2AX (S139) and pChk2 (Thr68) (3, 5, 9, 15, 16). As a result of DDR activation, DNA 
damage is repaired and its detrimental effects, including genomic instability, avoided. However, 
unrelieved oncogenic stress eventually results in a breach of this protective mechanism with 
subsequent progression to the malignant phenotype. A large body of published evidence has shown 
that DDR is activated during development of many tumor types (17). Several reports have shown 
immunohistochemical evidence that DDR proteins are highly expressed in precancerous lesions 
but less so in invasive cancers or corresponding normal tissues (4-8). It is therefore logical to 
explore these molecules as biomarkers of early cancer development and reasonable to hypothesize 
that visualization of components of the DDR might provide an excellent means of early cancer 
detection (9). It was shown previously that it is possible to image DNA damage using the 
prototypic SPECT imaging tracer, 111In-anti-γH2AX-TAT (10). We have used the same probe to 
test the hypothesis that DDR imaging can detect premalignant lesions in the BALB-neuT breast 
cancer model. 
Expression of γH2AX was significantly increased in hyperplastic and DCIS lesions in 
mice aged between 76 and 106 days compared to normal mammary fat pads (from young mice) 
and mature tumors (from older mice) (Fig. 1B). pATM, the kinase primarily responsible for 
H2AX phosphorylation to form γH2AX, was also upregulated during this period, while total 
ATM remained unchanged. In contrast to this robust activation of the DDR in BALB-neuT-
associated preneoplastic lesions, Reddy et al. found that the DDR was either weak or absent in 
hyperplastic lesions arising in some other transgenic mouse models of breast cancer. For 
example, only modest induction of γH2AX was observed in mammary lesions from MMTV-
ErbB2 transgenic animals (18). One possible explanation for this difference is that NeuT is more 
potently oncogenic than erbB2 (11), and so is more likely to cause DDR activation. Interestingly, 
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a somatic model of breast carcinogenesis, consisting of intraductal injection of the avian 
retrovirus RCAS carrying Erbb2 in MMTV-tva mice, was associated with marked stimulation of 
the DDR (18). 
Immunofluorescence staining for γH2AX in tumors from mice that had received Cy3- 
anti-γH2AX-TAT i.v. showed good co-localization of Cy3 with γH2AX foci; indicating that 
systemically administered antibody tracer is capable of penetrating tumor, internalizing into 
cancer cells and associating with its intranuclear target. Serial SPECT imaging using 111In-anti-
γH2AX-TAT in BALB-neuT mice showed that the γH2AX signal was greater in mammary fat 
pads of mice aged between 76 and 106 days, compared to animals in younger and older age 
groups. This was consistent with ex vivo immunostaining of mammary fat pads that revealed that 
γH2AX expression was highest in 76-106 day old mice. 
It was important to investigate whether 111In-anti-γH2AX-TAT itself increases DNA 
DSBs and, therefore, impairment of DNA repair, either through radiation dose deposition or by 
blocking signaling downstream of H2AX. However, we saw no evidence that 111In-anti-γH2AX-
TAT perturbs the system it is designed to image. Specifically, the number of γH2AX foci in 
tumor cells was unaffected by exposure to the probe and repeated administration of 111In-anti-
γH2AX-TAT or 111In-rIgG-TAT had no effect on tumor-free survival of animals (Fig. 4). 
111In-anti-γH2AX-TAT SPECT imaging of the DDR was superior to anatomical imaging 
methods. CT, acquired as anatomical reference during SPECT, provided images with poor soft-
tissue contrast such that only tumors >5 mm in diameter were detectable. T1-weighed MRI 
imaging and DCE-MRI imaging provided better contrast. However, the average age of mice 
when tumors first became detectable by DCE-MRI was 120 days, significantly later than 
detection by DDR-imaging using SPECT i.e. 96 days. 
The data presented in Figure 3, show that uptake of both 111In-anti-γH2AX-TAT 
and the non-specific probe is higher in carcinomas in older mice compared to 
intermediate-aged mice. This raises the question as to how the extent of uptake of 111In-
anti-γH2AX-TAT could be interpreted in a practical setting. Since SPECT imaging is 
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routinely combined with an anatomical imaging modality such as CT or MRI it is 
predicted that larger, late-stage lesions (i.e. the human equivalent of the mature cancers 
seen in mice > 106 days old) would be detected by correlative anatomical imaging. 
However, earlier stage lesions would be predicted to be positive for 111In-anti-γH2AX-
TAT uptake but lack CT/MRI evidence of a mass lesion. Thus it may be possible to 
distinguish between early and late stage lesions. 
These results provide proof-of-principle that it is possible to image γH2AX non-
invasively in preneoplastic lesions. However, further optimization of 111In-anti-γH2AX-TAT is 
needed, since the ratio of tumor to normal tissue contrast achieved in SPECT images was 
modest. Investigation of other tumor models is needed to explore the generalizability of these 
findings. Further work is also required to determine whether all lesions with constitutive DDR 
activation are destined to become invasive cancers, as this is likely to be a significant 
determinant of the utility of this imaging approach. It is possible that the DDR is particularly 
prominent in senescent premalignant cells, which may or may not progress beyond metaplasia, 
since the DDR itself acts as a barrier to tumorigenesis (19). Imaging γH2AX provides no 
information about other modifications of H2AX, such as ubiquitination and sumoylation, that 
may also follow genotoxic insults and be functionally important. 
A concerted effort is being made to develop imaging biomarkers for detection of 
preneoplasia in human cancers. The application of advanced endoscopic techniques to the 
diagnosis of premalignant lesions of the upper aerodigestive tract, bladder, colon, esophagus 
and bronchi is a major focus of research (20, 21). For example, confocal laser endomicroscopy 
(CLE) has recently been confirmed to significantly improve the identification of dysplasia in 
Barrett’s esophagus when combined with high-definition white light endoscopy (HD-WLE) 
(22). Optical and fluorescence endoscopic imaging techniques hold promise as accurate 
methods for distinguishing preneoplastic from invasive lesions, but visualization is limited to a 
depth of a few mm or less and so they are not suitable for the diagnosis of endoscopically 
inaccessible or deep-seated lesions. Increasingly, the merits of functional MRI imaging for the 
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detection and characterization of precancerous lesions in the breast are being explored. For 
example, diffusion-weighted imaging helped differentiate high-risk breast lesions requiring 
further investigation from benign lesions (23). However, the specificity of these methods is not 
yet sufficient for widespread adoption in the clinic and further research is required to develop 
clinically robust imaging systems for the detection of breast preneoplasia. 
The approach of DNA damage imaging has potential applications in the early detection 
of cancer and screening cancer-prone individuals (such as those with hereditary non-polyposis 
colorectal carcinoma, BRCA2 mutations and Peutz-Jeghers syndrome). Also the ability to image 
the DDR non-invasively would enable the response to DDR-targeted drugs to be monitored and 
might be useful in the development of cancer prevention strategies. Also, because DDR 
activation is a common phenomenon during tumorigenesis, γH2AX-targeted molecular imaging 
may be applicable to early detection of several types of cancer. 
 
CONCLUSION  
 
DDR-imaging using 111In-anti-γH2AX-TAT identified mammary tumors significantly 
earlier than MRI. Imaging the DDR holds promise for the detection of preneoplasia and as a 
technique for screening cancer-prone individuals. 
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FIGURE LEGENDS 
Figure 1: Mammary fat pads, or mammary fat pad tumors were harvested from BALB-neuT 
mice of various ages. (A) Tissues were frozen, sectioned and stained with haematoxylin/eosin, 
or immunostained for γH2AX, pATM or ATM. Representative images are shown (scale bar = 
10 µm). (B) The number of γH2AX foci per cell in harvested tissues was counted (one outlier 
depicted in grey), * P<0.05. 
Figure 2: (A) Groups of 3 BALB-neuT or BALB/c WT mice aged 76-106 days received Cy3-
anti-γH2AX-TAT or PBS i.v. Fluorescence images were acquired at 24 h p.i. (B) Mammary fat 
pads were removed, frozen, sectioned and stained for γH2AX, and counterstained with DAPI to 
visualize the nucleus (blue). Colocalization of γH2AX (green) and Cy3-anti-γH2AX-TAT (red) 
is observed (scale bar = 10 µm). 
Figure 3: BALB-neuT mice of different ages received 111In-anti-γH2AX-TAT or 111In-rIgG-
TAT i.v. at weekly intervals for up to 5 weeks. SPECT images were acquired 24 h p.i. (A) 
Maximum intensity projections (MIP) of representative animals. White circles denote areas of 
tumor development. (B) The uptake of 111In in mammary tissue was quantified by VOI analysis. 
For 111In-anti-γH2AX-TAT or 111In-rIgGTAT observations were assigned to three groups by age 
and then within each age group the average observation for each mouse was calculated. The 
height of each bar represents the mean of these averaged observations and the error bars are +/- 
the standard error of the mean, * P<0.05. (C) As in (B), but without age-stratification of results. 
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Figure 4: Kaplan-Meier plot comparing tumor-free survival of control BALB-neuT mice (that 
did not receive imaging probes) to that of mice that were imaged on multiple occasions using 
111In-anti-γH2AX-TAT or 111In-rIgG-TAT. 
Figure 5: (A) T1-weighed images of BALB-neuT mice of varying ages were acquired on a 4.7 T 
MRI scanner. DCE-MRI: Repeated T1-weighed images were acquired after injection of 
gadodiamide, and the integrated signal enhancement (area under the curve; AUC) was calculated 
on a pixel-per-pixel basis. (B) Kaplan-Meier plot comparing the time to detection of 
precancerous lesions and tumors through palpation, DCE-MRI, all SPECT imaging (111In-anti-
γH2AX-TAT or 111In-rIgG-TAT) and 111In-anti-γH2AX-TAT SPECT designated as positive 
when the uptake of 111In-anti-γH2AX-TAT ≥ 5 %ID/g. 
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